AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 21 min read$OBIO

Sherman Darren sold $74K of OBIO

Sherman Darren (See Remarks) sold 15,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $4.94 on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sherman Darren
Published Sep 2, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 9:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$OBIO
Neutral
medium confidence
Mentioned
$OBIO
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OBIONeutralLow
01

Why it matters

The disclosed sale is modest relative to total holdings and unlikely to move the stock materially.

02

Market read

Primary insider sale; low trading relevance but provides transparency for investors.

03

What to watch

Potential upcoming clinical data could outweigh the sale impact.

Relevance 2/10Novelty 4/10Timing: post‑market filing on 2026‑09‑02

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$OBIONeutralMedium confidence
Context

Officer/director sold 15,000 shares for $74,100 via a 10b5‑1 plan on 2026‑09‑01.

Expected impact

Slight downward bias in short term.

Evidence & confidence

The sale represents a modest fraction of holdings and is pre‑arranged, so market reaction is expected to be limited.

Market effects

Sector

None significant for the biotech sector.

Regional

No regional effect.

Global

Limited to OBIO shareholders.

Counterpoint

What could challenge this read

Insider may be diversifying, not signaling lack of confidence.

Key entities

  • company
    Orchestra BioMed Holdings, Inc.

    Biotech firm listed on NASDAQ under ticker OBIO.

  • insider
    Sherman Darren

    Officer and director of OBIO.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

OBIO insider trading history →

Related articles

AUG 19
$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

rttnews.com3 min
SEP 10
$DELLLow

Silver Lake Partners V DE (AIV), L.P. (Durban Egon) sold $15.0M of DELL (indirect holdings)

Silver Lake Partners V DE (AIV), L.P. sold 28,696 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $521.34 ($515.53–$529.16, $14.96M total) across 15 trades on 2026-09-04. Filed jointly with Silver Lake Technology Associates V, L.P. (Director), SLTA V (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).

SEC EDGAR1 min